Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

BMC Musculoskeletal Disorders

Volumn 18, Issue 1, 2017, Pages

  Adachi, Jonathan D ^a   Bone, Henry G ^b   Daizadeh, Nadia S ^c   Dakin, Paula ^c   Papapoulos, Socrates ^d   Hadji, Peyman ^e   Recknor, Chris ^f   Bolognese, Michael A ^g   Wang, Andrea ^c   Lin, Celia J F ^c   Wagman, Rachel B ^c   Ferrari, Serge ^h  

^a MCMASTER UNIVERSITY   (Canada)

^b Michigan Bone and Mineral Clinic   (United States)

^c AMGEN INC   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e KRANKENHAUS NORDWEST   (Germany)

^f United Osteoporosis Centers   (United States)

^g Bethesda Health Research Center   (United States)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Denosumab; Extension study; FREEDOM; Osteoporosis; Selection bias

Indexed keywords

DENOSUMAB; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE DENSITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONVERTEBRAL FRACTURE; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; MALE; MIDDLE AGED; PATIENT DROPOUT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; FEMALE; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PATIENT DROPOUTS; TREATMENT OUTCOME;

EID: 85018165299     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-017-1520-6     Document Type: Article

References (12)

1. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65.
2. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694-701.
3. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483-92.
4. Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen JE, et al. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res. 2014;29(9):2051-6.
5. Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, et al. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int. 2015;26:2763-71.
6. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773-83.
7. Papapoulos S, Lippuner K, Roux C, Lin CJ, Lewiecki EM, Brandi ML, et al. Effects of up to 8 years of denosumab treatment in women with postmenopausal osteoporosis: Results: from the first 5 years of the FREEDOM extension. Aust J Ageing. 2014;33 Suppl 1:[abstract] 14.
8. Adachi JD, Lin C, Ho PR, M.A. B, Bone HG, Hadji P, et al. Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years. http://acrabstracts.org/abstract/changes-in-subject-characteristics-in-the-denosumab-pivotal-fracture-trial-and-its-extension-for-up-to-8-years/. 2014;2014 ACR/ARHP Annual Meeting:Abstract 2254.
9. Zhao Y, Herring AH, Zhou H, Ali MW, Koch GG. A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring. J Biopharm Stat. 2014;24(2):229-53.
10. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987.
11. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27(3):687-93.
12. Vittinghoff E, McCulloch CE, Woo C, Cummings SR. Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med. 2010;29(10):1127-36.